产品
编 号：F116620
分子式：C20H23NO4
分子量：341.4
分子式：C20H23NO4
分子量：341.4
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
50mg
询价
询价
1g
询价
询价
结构图
CAS No: 131179-95-8
产品详情
生物活性：
Efaproxiral is a haemoglobin (Hb) synthetic allosteric modifier, decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy .
体内研究：
Efaproxiral (150 mg/kg, i.p.) increase tumor oxygenation，and increase the tumor growth inhibition of radiotherapy over 5 days of treatment.Efaproxiral reduces hemoglobin-oxygen binding affinity, which facilitates oxygen release from hemoglobin into surrounding tissues and potentially increases the pO(2) of the tumorsAnimal Model:Female C3H/HEJ mice (18–20 g), with radiation-induced fibrosarcoma tumor (RIF-1) cells xenograft
Dosage:150 mg/kg
Administration:Intraperitoneal injection; prior to X Irradiation (4 Gy/day), for 5 days
Result:Significantly increased tumor oxygenation by 8.4 to 43.4 mmHg within 5 days, with maximum increases at 22–31 minutes after treatment.
体外研究：
Efaproxiral binds to only one pair of symmetry-related sites in the Hb central water cavity.Efaproxiral readily crosses the red cell membrane in the presence of serum albumin solutions.Efaproxiral is not inhibited from entering erythrocytes in the presence of an anion-channel blocking agent (DIDS).
Efaproxiral is a haemoglobin (Hb) synthetic allosteric modifier, decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy .
体内研究：
Efaproxiral (150 mg/kg, i.p.) increase tumor oxygenation，and increase the tumor growth inhibition of radiotherapy over 5 days of treatment.Efaproxiral reduces hemoglobin-oxygen binding affinity, which facilitates oxygen release from hemoglobin into surrounding tissues and potentially increases the pO(2) of the tumorsAnimal Model:Female C3H/HEJ mice (18–20 g), with radiation-induced fibrosarcoma tumor (RIF-1) cells xenograft
Dosage:150 mg/kg
Administration:Intraperitoneal injection; prior to X Irradiation (4 Gy/day), for 5 days
Result:Significantly increased tumor oxygenation by 8.4 to 43.4 mmHg within 5 days, with maximum increases at 22–31 minutes after treatment.
体外研究：
Efaproxiral binds to only one pair of symmetry-related sites in the Hb central water cavity.Efaproxiral readily crosses the red cell membrane in the presence of serum albumin solutions.Efaproxiral is not inhibited from entering erythrocytes in the presence of an anion-channel blocking agent (DIDS).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备